Distinguishing dementia with Lewy bodies from Alzheimer's disease has been notoriously difficult for clinicians, often leading to inappropriate medications that can worsen symptoms. This diagnostic uncertainty affects thousands of patients who experience hallucinations, movement problems, and cognitive decline but receive delayed or incorrect treatment.
A new cerebrospinal fluid test measuring DOPA decarboxylase enzyme levels demonstrated over 90% accuracy in identifying Lewy body disorders across 1,173 patients in multiple clinical cohorts. The enzyme showed 2.5-fold higher concentrations in dementia with Lewy bodies and Parkinson's disease compared to healthy controls, and 1.9-fold higher levels versus Alzheimer's patients. Two separate immunoassay methods confirmed these findings across diverse patient populations, including 78 cases with autopsy-confirmed diagnoses.
This biomarker addresses a critical gap in neurodegeneration diagnostics, where current methods rely heavily on clinical observation and expensive brain imaging. The enzyme's elevation correlates with motor symptoms but not their severity, suggesting it reflects the underlying disease process rather than symptom progression. Brain tissue analysis revealed the enzyme co-localizes with alpha-synuclein protein deposits in the substantia nigra, the brain region most affected in these disorders. While promising, the test requires lumbar puncture for fluid collection, which may limit routine use. The research represents a significant advance toward objective diagnosis of Lewy body disorders, potentially enabling earlier, more targeted treatment decisions. However, broader validation across different populations and healthcare settings will be necessary before widespread clinical adoption.